Retour aux projets

18929.1 PFLS-LS

DUAL CYTOKINE-ANTIBODY FUSIONS: next-generation antibody products for a selective modulation of the activity of the immune system at the site of disease

Résumé

DUAL CYTOKINE-ANTIBODY FUSIONS: next-generation antibody products for a selective modulation of the activity of the immune system at the site of disease

Textes supplémentaires

Abstract

The use of recombinant antibodies as delivery vehicles promises to greatly enhance the therapeutic index of pro-inflammatory and anti-inflammatory cytokines. However, current generation immunocytokines do not elicit cures in vivo whereas combination immunocytokine therapies can. This project aims to develop 'second generation' immunocytokines to capitalize on this observation by combining synergistic cytokine pairs into a single therapeutic molecule

Participants

Catherine Hutchinson

Wirtschaftspartner

catherine.hutchinson@philochem.ch

Philochem AG CHE-113.181.443 Catherine Hutchinson Libernstrasse 3 8112 Otelfingen ZH CH

Dario Neri

Kontaktperson

dario.neri@pharma.ethz.ch

ETH Zürich Inst. of Pharmac. Sciences Dario Neri HCI G496 / Wolfgang-Pauli-Strasse 10 8093 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2016-08-31
Date de fin
2017-08-31
Coûts totaux approuvés
CHF 55814.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%